share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

Benzinga ·  Apr 26 05:35

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment